Eli Lilly’s Elanco takes over Pfizer’s European animal health portfolio
09 Mar 2010
The animal health division of Eli Lilly and Company, Elanco, has signed an agreement to acquire the European rights to a portfolio of certain animal health products of Pfizer, for an undisclosed sum.
The products, including vaccines, parasiticides and feed additives, are used in both the production of animal and companion animal markets, and have been marketed by Pfizer and Wyeth's Fort Dodge operations.
The European Commission had asked Pfizer to divest these products as a pre-condition for approving Pfizer's $68-billion acquisition of Wyeth in January 2009, including Wyeth's Fort Dodge Animal Health business (See: Pfizer-Wyeth create $68-billion blockbuster deal).
To comply with European Commission rules, Pfizer had in September 2009 sold certain assets to Boehringer Ingelheim. Thos include, Pfizer's research and manufacturing facilities, located in Fort Dodge, Iowa, as well as related assets and intellectual property, primarily from Wyeth's Fort Dodge Animal Health portfolio in the US and Canada (See: Pfizer, Wyeth to sell animal drugs business to Boehringer).
Under the terms of yesterday's agreement, Lilly will also acquire a Pfizer's biological manufacturing facility in Sligo, Ireland, currently used in the production of animal vaccines.
Aall Sligo employees will be offered positions with Elanco.
